BG108420A - Нови индолови производни с 5-нт6 рецепторен афинитет - Google Patents
Нови индолови производни с 5-нт6 рецепторен афинитетInfo
- Publication number
- BG108420A BG108420A BG108420A BG10842003A BG108420A BG 108420 A BG108420 A BG 108420A BG 108420 A BG108420 A BG 108420A BG 10842003 A BG10842003 A BG 10842003A BG 108420 A BG108420 A BG 108420A
- Authority
- BG
- Bulgaria
- Prior art keywords
- receptor affinity
- indole derivatives
- new indole
- group
- isomers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Съединенията или техни отделни изомери, рацемични или нерацемични смеси от изомери, или фармацевтично приемливи соли или солвати, които имат 5-НТ6 рецепторен афинитет, са представени с формула, в която един от R5, R6 или R7 означава група с обща формула В, като W означава -СН-група или азотен атом, и всички останали заместители имат посочените в описанието значения. Изобретението се отнася и до съдържащите ги фармацевтични състави, до използването им като лекарствени средства и до методи за тяхното получаване. а
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29670501P | 2001-06-07 | 2001-06-07 | |
US34021201P | 2001-12-13 | 2001-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
BG108420A true BG108420A (bg) | 2005-02-28 |
Family
ID=26969776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108420A BG108420A (bg) | 2001-06-07 | 2003-12-05 | Нови индолови производни с 5-нт6 рецепторен афинитет |
Country Status (33)
Country | Link |
---|---|
US (3) | US6787535B2 (bg) |
EP (1) | EP1401813B1 (bg) |
JP (1) | JP4187642B2 (bg) |
KR (1) | KR100600240B1 (bg) |
CN (1) | CN1257892C (bg) |
AR (1) | AR036233A1 (bg) |
AT (1) | ATE353318T1 (bg) |
AU (1) | AU2002310747B2 (bg) |
BG (1) | BG108420A (bg) |
BR (1) | BR0210929A (bg) |
CA (1) | CA2449874C (bg) |
CO (1) | CO5630036A2 (bg) |
CZ (1) | CZ20033529A3 (bg) |
DE (1) | DE60218037T2 (bg) |
ES (1) | ES2280546T3 (bg) |
HK (1) | HK1068610A1 (bg) |
HR (1) | HRP20030984A2 (bg) |
HU (1) | HUP0401307A2 (bg) |
IL (1) | IL158997A0 (bg) |
MA (1) | MA27032A1 (bg) |
MX (1) | MXPA03011244A (bg) |
NO (1) | NO20035359D0 (bg) |
NZ (1) | NZ529631A (bg) |
PA (1) | PA8546601A1 (bg) |
PE (1) | PE20030039A1 (bg) |
PL (1) | PL367305A1 (bg) |
RU (1) | RU2294932C2 (bg) |
SK (1) | SK16052003A3 (bg) |
TW (1) | TW591015B (bg) |
UY (1) | UY27322A1 (bg) |
WO (1) | WO2002098857A1 (bg) |
YU (1) | YU96103A (bg) |
ZA (1) | ZA200309005B (bg) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4731114B2 (ja) | 2001-06-11 | 2011-07-20 | プロキシマゲン・リミテッド | 置換スルホンアミド化合物、cns障害、肥満およびii型糖尿病の処置のための医薬としてのそれらの使用方法 |
EP1414442A1 (en) * | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
BRPI0308696B8 (pt) | 2002-03-27 | 2021-05-25 | Axovant Sciences Gmbh | composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos |
TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
EP1897881A3 (en) * | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
WO2004000828A1 (en) * | 2002-06-20 | 2003-12-31 | Biovitrum Ab | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
NZ537982A (en) * | 2002-09-17 | 2007-05-31 | Hoffmann La Roche | 2,7-substituted indoles and their use as 5-HT6 modulators |
BRPI0407493A (pt) * | 2003-02-14 | 2006-02-14 | Wyeth Corp | derivados heterociclil-3-sulfinilazaindol ou -azaindazol como ligantes de 5-hidroxitriptamina-6 |
AU2004226838B8 (en) | 2003-04-04 | 2009-06-11 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
WO2005012254A1 (en) | 2003-07-22 | 2005-02-10 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto |
US20050250794A1 (en) * | 2003-12-19 | 2005-11-10 | Andrew Napper | Methods of treating a disorder |
KR20060127886A (ko) * | 2003-12-19 | 2006-12-13 | 바이오비트럼 에이비 | 5-ht6 수용체-관련 장애의 예방 및 치료에 사용될 수있는, 신규한 벤조퓨란 유도체 |
SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
BRPI0417858B1 (pt) | 2003-12-23 | 2017-10-10 | H. Lundbeck A/S | Derivative compounds of aniline and pharmaceutical composition that understand it |
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
PE20060373A1 (es) * | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
AR052308A1 (es) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
ES2359725T3 (es) * | 2004-09-30 | 2011-05-26 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos. |
WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
AR054393A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
CA2619010C (en) * | 2005-08-15 | 2013-10-01 | Wyeth | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
ES2274725B1 (es) * | 2005-11-08 | 2008-04-01 | Laboratorios Del Dr. Esteve, S.A. | Indeno derivados, su preparacion y su uso como medicamentos. |
CN101370775A (zh) * | 2006-01-13 | 2009-02-18 | 惠氏公司 | 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚 |
CA2637531A1 (en) * | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
WO2008055808A1 (en) * | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Indole and benzofuran 2-carboxamide derivatives |
ATE491685T1 (de) | 2007-01-08 | 2011-01-15 | Suven Life Sciences Ltd | 5-(heterocyclyl)alkyl-n- (arylsulfonyl)indolverbindungen und ihre verwendung als 5-ht6-liganden |
ES2533902T3 (es) * | 2007-01-08 | 2015-04-15 | Suven Life Sciences Limited | Compuestos de 4-(heterociclil)alquil-N-(arilsulfonil)indol y su uso como ligandos del 5-HT6 |
US20080200471A1 (en) * | 2007-02-16 | 2008-08-21 | Memory Pharmaceuticals Corporation | 6' substituted compounds having 5-ht6 receptor affinity |
US20100041672A1 (en) * | 2007-03-21 | 2010-02-18 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
DK2155674T3 (da) | 2007-05-03 | 2011-09-26 | Suven Life Sciences Ltd | Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander |
US20080318941A1 (en) * | 2007-05-24 | 2008-12-25 | Memory Pharmaceuticals Corporation | 4' substituted compounds having 5-ht6 receptor affinity |
AU2008286760A1 (en) * | 2007-08-15 | 2009-02-19 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-HT6 receptor affinity |
BRPI0816571A2 (pt) | 2007-10-26 | 2015-12-22 | Suven Life Sciences Ltd | "composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6" |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
CN101952278A (zh) * | 2008-02-15 | 2011-01-19 | 弗·哈夫曼-拉罗切有限公司 | 3-烷基-哌嗪衍生物及其用途 |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
MX2011002884A (es) | 2008-09-17 | 2011-04-21 | Suven Life Sciences Ltd | Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6. |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
JP5628937B2 (ja) | 2010-01-05 | 2014-11-19 | スベン ライフ サイエンシズ リミティド | 5−ht6受容体リガンドとしてのスルホン化合物 |
WO2012024620A2 (en) | 2010-08-20 | 2012-02-23 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
CN102924359B (zh) * | 2012-10-30 | 2015-03-11 | 中国科学院烟台海岸带研究所 | 一种一锅法合成取代吲哚类化合物的方法 |
WO2015090233A1 (en) | 2013-12-20 | 2015-06-25 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
AU2015286049B2 (en) | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
MX2017016413A (es) | 2015-06-12 | 2018-08-01 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem. |
MX2018000465A (es) | 2015-07-15 | 2018-09-17 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0773942A1 (en) * | 1994-07-26 | 1997-05-21 | Pfizer Inc. | 4-indole derivatives as serotonin agonists and antagonists |
GB9517559D0 (en) * | 1995-08-26 | 1995-10-25 | Smithkline Beecham Plc | Novel compounds |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
BR9809092A (pt) * | 1997-04-18 | 2002-01-22 | Smithkline Beecham Plc | Derivados de indol tendo atividade combinada de antagonista de receptor de 5ht1a, 5ht1b e 5ht1d |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
MXPA01010655A (es) * | 1999-04-21 | 2002-11-04 | Allelix Biopharma | Compuestos de piperidin-indol que tienen afinidad por 5-ht6. |
WO2001032660A1 (en) * | 1999-11-05 | 2001-05-10 | Nps Allelix Corp. | Compounds having 5-ht6 receptor antagonist activity |
CN1222511C (zh) * | 2000-11-02 | 2005-10-12 | 惠氏公司 | 作为5-羟色胺-6配体的1-芳基-或1-烷基磺酰基-杂环基吲哚 |
US7034029B2 (en) * | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
HUP0400684A2 (hu) * | 2000-12-22 | 2004-07-28 | Wyeth | 5-Hidroxitriptamin-6-ligandumként használható heterociklilindazol- és -azaindazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények |
DE60119982T2 (de) * | 2000-12-22 | 2006-12-21 | Wyeth | Heterozyklylalkylindole oder -azaindole als 5-hydroxytryptamine-6 liganden |
TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
EP1385842A1 (en) * | 2001-04-20 | 2004-02-04 | Wyeth | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
EP1414442A1 (en) * | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
PL376479A1 (en) * | 2002-10-18 | 2005-12-27 | F.Hoffmann-La Roche Ag | 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity |
-
2002
- 2002-05-29 RU RU2003136731/04A patent/RU2294932C2/ru not_active IP Right Cessation
- 2002-05-29 CA CA002449874A patent/CA2449874C/en not_active Expired - Fee Related
- 2002-05-29 WO PCT/EP2002/005890 patent/WO2002098857A1/en active IP Right Grant
- 2002-05-29 JP JP2003501846A patent/JP4187642B2/ja not_active Expired - Fee Related
- 2002-05-29 HU HU0401307A patent/HUP0401307A2/hu unknown
- 2002-05-29 IL IL15899702A patent/IL158997A0/xx unknown
- 2002-05-29 MX MXPA03011244A patent/MXPA03011244A/es active IP Right Grant
- 2002-05-29 AU AU2002310747A patent/AU2002310747B2/en not_active Ceased
- 2002-05-29 AT AT02735394T patent/ATE353318T1/de not_active IP Right Cessation
- 2002-05-29 DE DE60218037T patent/DE60218037T2/de not_active Expired - Lifetime
- 2002-05-29 EP EP02735394A patent/EP1401813B1/en not_active Expired - Lifetime
- 2002-05-29 YU YU96103A patent/YU96103A/sh unknown
- 2002-05-29 SK SK16052003A patent/SK16052003A3/sk unknown
- 2002-05-29 BR BR0210929-8A patent/BR0210929A/pt not_active Application Discontinuation
- 2002-05-29 ES ES02735394T patent/ES2280546T3/es not_active Expired - Lifetime
- 2002-05-29 CZ CZ20033529A patent/CZ20033529A3/cs unknown
- 2002-05-29 NZ NZ529631A patent/NZ529631A/en unknown
- 2002-05-29 CN CNB028115244A patent/CN1257892C/zh not_active Expired - Fee Related
- 2002-05-29 PL PL02367305A patent/PL367305A1/xx not_active Application Discontinuation
- 2002-05-29 KR KR1020037016022A patent/KR100600240B1/ko not_active IP Right Cessation
- 2002-06-03 TW TW091111843A patent/TW591015B/zh not_active IP Right Cessation
- 2002-06-04 AR ARP020102066A patent/AR036233A1/es not_active Application Discontinuation
- 2002-06-04 PA PA20028546601A patent/PA8546601A1/es unknown
- 2002-06-06 US US10/164,660 patent/US6787535B2/en not_active Expired - Fee Related
- 2002-06-06 UY UY27322A patent/UY27322A1/es not_active Application Discontinuation
- 2002-06-07 PE PE2002000481A patent/PE20030039A1/es not_active Application Discontinuation
-
2003
- 2003-11-19 ZA ZA200309005A patent/ZA200309005B/en unknown
- 2003-11-26 HR HR20030984A patent/HRP20030984A2/hr not_active Application Discontinuation
- 2003-12-02 NO NO20035359A patent/NO20035359D0/no not_active Application Discontinuation
- 2003-12-02 CO CO03106073A patent/CO5630036A2/es not_active Application Discontinuation
- 2003-12-03 MA MA27422A patent/MA27032A1/fr unknown
- 2003-12-05 BG BG108420A patent/BG108420A/bg unknown
-
2004
- 2004-06-25 US US10/876,863 patent/US20040248902A1/en not_active Abandoned
-
2005
- 2005-01-27 HK HK05100706A patent/HK1068610A1/xx not_active IP Right Cessation
- 2005-03-03 US US11/071,726 patent/US20050171118A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG108420A (bg) | Нови индолови производни с 5-нт6 рецепторен афинитет | |
MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
HK1070054A1 (en) | Arylsulfonyl derivatives with5-ht6 receptor affinity | |
TNSN03110A1 (en) | Azaindoles. | |
IS6520A (is) | Ný efnasambönd | |
PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
MX2007004740A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica. | |
PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
SE0102055D0 (sv) | New Compounds | |
MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
HUP0002929A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0303513A2 (hu) | Szubsztituált pirazinkinoxalin-származékok mint szerotonin receptor agonisták és antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
RS56104A (en) | Imidazoquinoline derivatives | |
CA2438813A1 (en) | Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as ip antagonists | |
MXPA05011476A (es) | Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2. | |
PL1660484T3 (pl) | Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1 | |
SE0301371D0 (sv) | New Compounds | |
HUP0303608A2 (hu) | Hiperaktív húgyhólyag kezelésére alkalmas gyógyszer | |
ECSP034870A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
AP2001002179A0 (en) | 2-Aminocarbonyl-9h-purine derivatives. |